Johnson & Johnson gains 4% after publishing Q2 results

6:03 PM 17 July 2024

Johnson & Johnson (JNJ.US) shares are gaining 4% during today's session, after the drug and healthcare products manufacturer reported second-quarter results that exceeded analysts' expectations. On the other hand, the company lowered its adjusted earnings per share forecast for the full year due to costs associated with mergers and acquisitions resulting from recent transactions. However, it seems that in the eyes of investors, higher costs incurred now will be offset by higher profits in the future.

ANNUAL FORECAST

  • Expected adjusted earnings per share (EPS) $9.97 to $10.07, previously $10.57 to $10.72
  • Expected adjusted operating EPS $10 to $10.10, previously $10.60 to $10.75
  • Expected revenues between $88 billion to $88.4 billion (unchanged)

SECOND QUARTER RESULTS

  • Adjusted EPS $2.82, estimated $2.71
  • Revenues $22.45 billion, estimated $22.32 billion
  • MedTech revenues $7.96 billion, estimated $8.22 billion
  • Pharmaceutical division revenues $14.49 billion, estimated $14.08 billion

Source: xStation

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits